LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Lista de Ações・CytoSorbents Corp

Search

CytoSorbents Corp

Fechado

SetorSaúde

0.39 -9.3

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.39

Máximo

0.41

Indicadores-chave
By Trading Economics
Rendimento	368K -5.1M
Vendas	-370K 8.9M
EPS	-0.08
Margem de lucro	-57.863
Funcionários	129
EBITDA	648K -3M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+82.93% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-14M 26M
Abertura anterior	9.69
Fecho anterior	0.39

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de jun. de 2026, 23:36 UTC

Ganhos

Correction to Oracle Reports Higher 4Q Profit Article

10 de jun. de 2026, 23:19 UTC

Ações em Alta

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 de jun. de 2026, 23:09 UTC

Grandes Movimentos do Mercado

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 de jun. de 2026, 23:04 UTC

Ganhos

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 de jun. de 2026, 20:44 UTC

Grandes Movimentos do Mercado

Caterpillar Raises Quarterly Dividend 8%

10 de jun. de 2026, 23:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Northern Star Should Take No Options Off The Table

10 de jun. de 2026, 23:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 de jun. de 2026, 23:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 de jun. de 2026, 23:47 UTC

Conversa de Mercado

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 de jun. de 2026, 23:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 de jun. de 2026, 23:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 de jun. de 2026, 23:38 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

10 de jun. de 2026, 23:38 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 de jun. de 2026, 23:38 UTC

Conversa de Mercado

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 de jun. de 2026, 23:32 UTC

Conversa de Mercado

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 de jun. de 2026, 23:20 UTC

Conversa de Mercado

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 de jun. de 2026, 22:05 UTC

Conversa de Mercado

Correction to Bank of Canada Stays on Hold Market Talk

10 de jun. de 2026, 21:57 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:52 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:35 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:22 UTC

Ganhos

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Tech, Media & Telecom Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de jun. de 2026, 20:39 UTC

Conversa de Mercado

Ganhos

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 de jun. de 2026, 20:34 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 20:33 UTC

Ganhos

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 de jun. de 2026, 20:33 UTC

Conversa de Mercado

Ganhos

Global Equities Roundup: Market Talk

10 de jun. de 2026, 20:33 UTC

Conversa de Mercado

Ganhos

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

82.93% parte superior

Previsão para 12 meses

Média 0.75 USD 82.93%

Máximo 0.75 USD

Mínimo 0.75 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

0

Comprar

1

Manter

0

Vender

Com base em 1 analistas que deram avaliações de ações para CytoSorbents Corp - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Outras ações do setor

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat